Estados Unidos · Plataformas y datos · MarketBeat

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Publicado por MarketBeat · Estados Unidos hace 2 h

Travere Therapeutics (NASDAQ:TVTX) reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

También te puede interesar

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Apple’s iPhone business is booming. Here’s why the stock is falling anyway.

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Compartir

También te puede interesar

Clorox forecasts 3.5%-4.5% organic sales growth as input cost inflation rises to $240M

JAKKS Pacific: 3 Key Takeaways for Long-Term Investors

Apple’s iPhone business is booming. Here’s why the stock is falling anyway.

Disney eyes thousands of layoffs, asks managers to target 20% savings, Bloomberg News reports

Stock market after midterm elections: What S&P 500 history shows

Locksley Resources Options Expire Without Exercise